Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research note published on Monday,Benzinga reports. They currently have a $18.00 price target on the stock.

A number of other equities research analysts have also recently weighed in on TNYA. Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Chardan Capital decreased their target price on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Canaccord Genuity Group restated a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Tenaya Therapeutics has a consensus rating of “Buy” and an average price target of $14.75.

Tenaya Therapeutics Price Performance

NASDAQ TNYA opened at $3.29 on Monday. Tenaya Therapeutics has a 52 week low of $1.61 and a 52 week high of $7.01. The firm has a market cap of $260.64 million, a PE ratio of -2.28 and a beta of 2.34. The business’s fifty day simple moving average is $2.09 and its 200-day simple moving average is $2.84.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07. Research analysts expect that Tenaya Therapeutics will post -1.35 EPS for the current year.

Hedge Funds Weigh In On Tenaya Therapeutics

Several large investors have recently bought and sold shares of TNYA. Synovus Financial Corp purchased a new stake in Tenaya Therapeutics during the 3rd quarter worth about $28,000. The Manufacturers Life Insurance Company lifted its stake in Tenaya Therapeutics by 43.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares during the last quarter. Algert Global LLC acquired a new position in Tenaya Therapeutics in the second quarter valued at approximately $74,000. SG Americas Securities LLC purchased a new position in Tenaya Therapeutics in the third quarter valued at approximately $49,000. Finally, XTX Topco Ltd raised its holdings in Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares in the last quarter. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.